Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. VAXX, ATXI, UPC, CANF, EVFM, VCNX, ADXS, GRTX, ASLN, and PTPIShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Vaxxinity (VAXX), Avenue Therapeutics (ATXI), Universe Pharmaceuticals (UPC), Can-Fite BioPharma (CANF), Evofem Biosciences (EVFM), Vaccinex (VCNX), Ayala Pharmaceuticals (ADXS), Galera Therapeutics (GRTX), ASLAN Pharmaceuticals (ASLN), and Petros Pharmaceuticals (PTPI). These companies are all part of the "pharmaceutical preparations" industry. Athersys vs. Its Competitors Vaxxinity Avenue Therapeutics Universe Pharmaceuticals Can-Fite BioPharma Evofem Biosciences Vaccinex Ayala Pharmaceuticals Galera Therapeutics ASLAN Pharmaceuticals Petros Pharmaceuticals Vaxxinity (NASDAQ:VAXX) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do insiders & institutionals believe in VAXX or ATHX? 82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, VAXX or ATHX? Vaxxinity has higher earnings, but lower revenue than Athersys. Vaxxinity is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.04Athersys$146K0.00-$72.53M-$2.03N/A Which has more volatility and risk, VAXX or ATHX? Vaxxinity has a beta of 17.1, meaning that its stock price is 1,610% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500. Does the media refer more to VAXX or ATHX? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Athersys'average media sentiment score. Company Overall Sentiment Vaxxinity Neutral Athersys Neutral Is VAXX or ATHX more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Athersys N/A N/A -223.03% SummaryVaxxinity beats Athersys on 6 of the 8 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$1.03B$6.02B$10.26BDividend YieldN/A4.84%5.66%4.69%P/E Ratio0.001.2985.3626.60Price / SalesN/A30.47583.50178.23Price / CashN/A17.6438.3262.20Price / BookN/A7.3112.736.54Net Income-$72.53M-$7.96M$3.30B$275.87M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024Gap DownVAXXVaxxinityN/A$0.02+100.0%N/A-95.0%$2.54MN/A-0.0490Gap DownATXIAvenue Therapeutics2.0656 of 5 stars$0.79-0.1%N/A-64.1%$2.51MN/A0.044UPCUniverse PharmaceuticalsN/A$4.33-4.3%N/AN/A$2.44M$19.29M0.00220CANFCan-Fite BioPharma2.6882 of 5 stars$0.620.0%$14.50+2,257.7%-75.8%$2.18M$560K-0.348Positive NewsGap DownEVFMEvofem Biosciences0.464 of 5 stars$0.01-2.9%N/A+8.2%$1.67M$11.39M-0.02120Gap UpVCNXVaccinex0.755 of 5 stars$0.62-16.2%N/A-71.7%$1.61M$388K-0.0140ADXSAyala PharmaceuticalsN/A$0.04-61.5%N/A+23.3%$1.49M$3.24M0.0020Gap UpGRTXGalera TherapeuticsN/A$0.02+0.5%N/A-75.7%$1.43MN/A-0.0530Gap DownASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330PTPIPetros PharmaceuticalsN/A$0.02-5.5%N/A-99.7%$751K$5.11M-0.0120Gap Down Related Companies and Tools Related Companies Vaxxinity Competitors Avenue Therapeutics Competitors Universe Pharmaceuticals Competitors Can-Fite BioPharma Competitors Evofem Biosciences Competitors Vaccinex Competitors Ayala Pharmaceuticals Competitors Galera Therapeutics Competitors ASLAN Pharmaceuticals Competitors Petros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
